Skip to main content

Currently Skimming:

Initiatives for 2010
Pages 10-10

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 10...
... Individuals from the federal govern- will examine progress made in the premarket drug safety sys ment, pharmaceutical industry, academia, industry, and pa- tem since the release of the IOM drug safety report and the tient groups will discuss the strengths and weaknesses of the passage of the FDA Amendments Act of 2007. The series will current regulatory science framework, and consider a range of also consider the challenges and policy issues that remain. A strategies for improving regulatory science, such as develop- fourth FDA Community Update will brief Washington policy ment of a scientific discipline of regulatory science, increased makers on the agency's progress in communicating benefits collaboration between regulatory and academic researchers, and risks of pharmaceuticals to the medical community.


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.